1. Home
  2. TYRA vs PLUS Comparison

TYRA vs PLUS Comparison

Compare TYRA & PLUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$30.53

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo ePlus inc.

PLUS

ePlus inc.

HOLD

Current Price

$79.24

Market Cap

2.2B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYRA
PLUS
Founded
2018
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.2B
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
TYRA
PLUS
Price
$30.53
$79.24
Analyst Decision
Strong Buy
Analyst Count
11
0
Target Price
$47.50
N/A
AVG Volume (30 Days)
949.6K
274.1K
Earning Date
05-06-2026
05-21-2026
Dividend Yield
N/A
1.20%
EPS Growth
N/A
24.20
EPS
N/A
5.03
Revenue
N/A
$2,442,549,000.00
Revenue This Year
N/A
$19.83
Revenue Next Year
N/A
$4.36
P/E Ratio
N/A
$15.75
Revenue Growth
N/A
18.07
52 Week Low
$9.10
$62.11
52 Week High
$40.65
$93.98

Technical Indicators

Market Signals
Indicator
TYRA
PLUS
Relative Strength Index (RSI) 52.01 41.24
Support Level $24.77 $77.97
Resistance Level $31.57 $90.93
Average True Range (ATR) 1.94 3.42
MACD 0.54 -0.41
Stochastic Oscillator 87.95 15.08

Price Performance

Historical Comparison
TYRA
PLUS

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About PLUS ePlus inc.

ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.

Share on Social Networks: